Thomas Wilder - President and CEO
Most recently led Sequent Medical, Inc., which was acquired by Terumo Corporation in 2016 for $380 million. Prior to joining Sequent, he was President and CEO of PhotoThera, Inc. Prior to this, he served as President and CEO of Micro Therapeutics, Inc. (MTIX), which was merged into ev3, Inc. (EVVV) in 2006, at a valuation of $360 million. Earlier in his career, held positions of increasing responsibility at Medtronic, Inc. (MDT). He currently serves on the Board of Directors of Penumbra, Inc. (PEN).
David Veino - Chief Operating Officer
Most recently, served as Vice President of Sales & Marketing (2015-2018) and Vice President of Marketing (2012-2015) at Cardiovascular Systems, Inc. (CSII), where he led the US commercialization strategy for both the Peripheral Vascular and Coronary segments, establishing market leadership in both categories. Prior to this, held key commercial leadership positions at Globus Medical (GMED), Stryker Interventional Spine (SYK) and other venture capital medical device start-up companies focused in cardiovascular disease.
William R. Patterson, PhD. - Chief Technical Officer
Prior to joining Neuros in January 2021, Bill was the CTO at MicroVention, Inc. (A Terumo Group Company) and led the development of many neurovascular devices and participated in their CE Mark approvals, 501k clearances, PMA approvals, and moderated a PMA Advisory Committee meeting. From 2010 to 2016, Bill was the VP of R&D & Operations at Sequent, and Terumo Corporation acquired Sequent Medical for up to $380M in 2016. He began his R&D medical device career at Baxter Healthcare Corporation (now Edwards Lifesciences Corporation) and worked in R&D leadership positions at companies (e.g. MicroTherapeutics, Inc that was merged into ev3 at a valuation of $360M) founded by former Baxter colleagues.
Zi-Ping Fang, Ph.D. - Chief Scientific Officer
PhD in Biomedical Engineering focused on neurostimulation technology from Case Western Reserve University. Over 25 years of neurostimulation R&D, pre-clinical and clinical research leading to FDA approval, including technology leadership and management and executive responsibility in neurostimulation startup business development and operations including Nevro and NeuroControl.
Melanie Parravi - Sr. Vice President of Quality & Regulatory Affairs.
Most recently, served as Vice President of Quality Assurance & Regulatory Compliance at Sequent Medical, Inc., acquired by Terumo Corporation in 2016, where she was instrumental in the development of the WEB Aneurysm Embolization System and in the procurement of both US and international regulatory approvals. Prior to this, served as Sr. Director, Quality Assurance for Covidien’s neurovascular division (formerly ev3/Micro Therapeutics, Inc.). Worked previously for J&J Biosense Webster and Allergan.
Amy Smith - Vice President, Global Marketing
Most recently served in Marketing and Sales leadership positions leading efforts to develop the market for balloon sinus dilation at Entellus Medical (2008-2018) through IPO in 2015 and subsequent acquisition by Stryker (SYK) for $662 million in 2018. Prior to Entellus, Amy served in marketing leadership roles at Boston Scientific Peripheral and Coronary Divisions and R&D and Engineering Management roles at SurModics and 3M.